In 2023, there were around 676 cases of chickenpox in Canada, a substantial decrease from almost 50 thousand in 1993. This statistic depicts the number of chickenpox, or varicella, cases in Canada from 1924 to 2023, by year.

NNDSS - Table II. Varicella to West Nile virus disease - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. ��� Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNet Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I. �� Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the Arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/document/SRCA_FINAL_REPORT_2006-2012_final.xlsx.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

Varicella in Africa – raw dataset. Data extracted from the included studies. (XLSX 44 kb)

Project Tycho datasets contain case counts for reported disease conditions for countries around the world. The Project Tycho data curation team extracts these case counts from various reputable sources, typically from national or international health authorities, such as the US Centers for Disease Control or the World Health Organization. These original data sources include both open- and restricted-access sources. For restricted-access sources, the Project Tycho team has obtained permission for redistribution from data contributors. All datasets contain case count data that are identical to counts published in the original source and no counts have been modified in any way by the Project Tycho team. The Project Tycho team has pre-processed datasets by adding new variables, such as standard disease and location identifiers, that improve data interpretabilty. We also formatted the data into a standard data format.

Each Project Tycho dataset contains case counts for a specific condition (e.g. measles) and for a specific country (e.g. The United States). Case counts are reported per time interval. In addition to case counts, datsets include information about these counts (attributes), such as the location, age group, subpopulation, diagnostic certainty, place of aquisition, and the source from which we extracted case counts. One dataset can include many series of case count time intervals, such as "US measles cases as reported by CDC", or "US measles cases reported by WHO", or "US measles cases that originated abroad", etc.

Depending on the intended use of a dataset, we recommend a few data processing steps before analysis:

• Analyze missing data: Project Tycho datasets do not inlcude time intervals for which no case count was reported (for many datasets, time series of case counts are incomplete, due to incompleteness of source documents) and users will need to add time intervals for which no count value is available. Project Tycho datasets do include time intervals for which a case count value of zero was reported.
• Separate cumulative from non-cumulative time interval series. Case count time series in Project Tycho datasets can be "cumulative" or "fixed-intervals". Cumulative case count time series consist of overlapping case count intervals starting on the same date, but ending on different dates. For example, each interval in a cumulative count time series can start on January 1st, but end on January 7th, 14th, 21st, etc. It is common practice among public health agencies to report cases for cumulative time intervals. Case count series with fixed time intervals consist of mutually exxclusive time intervals that all start and end on different dates and all have identical length (day, week, month, year). Given the different nature of these two types of case count data, we indicated this with an attribute for each count value, named "PartOfCumulativeCountSeries".

Objective To analyze the trends in the disease burden of varicella and herpes zoster among individuals aged ≥50 years in China from 1990 to 2021 and project future trends, providing evidence for varicella and herpes zoster prevention and control. ‌Methods Data on the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of varicella and herpes zoster among individuals aged 50 years and older in China and globally were extracted from the Global Burden of Disease (GBD) 2021 database. Comparisons were made between 2021 and the baseline year (1990) for these indicators. Joinpoint regression models were employed to dynamically analyze trends in disease burden. Decomposition analysis was conducted to identify key drivers of burden changes. Additionally, the Bayesian Age-Period-Cohort (BAPC) prediction model was utilized to fit age-standardized rates and forecast trends from 2022 to 2035. ‌Results In 2021, the age-standardized incidence rate (ASIR) of varicella and herpes zoster among the Chinese population aged 50 years and older was 726.99 per 100,000, showing a 0.01% increase compared to 1990. The age-standardized prevalence rate (ASPR), mortality rate (ASMR), and DALY rate (ASDR) were 134.09 per 100,000, 0.14 per 100,000, and 8.94 per 100,000, respectively, representing reductions of 0.08%, 88.54%, and 61.42% from 1990 levels. Females consistently exhibited higher disease burden than males. Joinpoint regression analysis revealed that ASIR and ASPR exhibited a significant upward trend during 2000–2005, followed by a sharp decline in 2005–2010, with greater fluctuations observed in females compared to males. In contrast, ASMR and ASDR demonstrated sustained downward trends. Global trends paralleled those observed in China. Population growth was identified as the primary driver of disease burden changes in both China and globally. Projection modeling predicted that by 2035, China's ASIR, ASPR, ASMR, and ASDR may reach 728.77 per 100,000, 145.62 per 100,000, 0.08 per 100,000, and 8.91 per 100,000, respectively. Notably, ASIR and ASPR are projected to exceed global levels, while ASMR and ASDR are anticipated to remain below global averages. ‌Conclusion varicella and herpes zoster imposes a higher incidence and prevalence burden among individuals aged 50 years and older in China compared to global levels, with a projected sustained increasing trend. The disease burden is consistently greater in females than in males, underscoring the urgent need for targeted interventions to mitigate its escalating impact.

Varicella Vaccines Market Outlook

According to our latest research, the global varicella vaccines market size reached USD 3.7 billion in 2024, driven by increasing vaccination coverage rates and heightened awareness of varicella-related complications. The market is projected to expand at a robust CAGR of 6.2% from 2025 to 2033, reaching a forecasted value of USD 6.34 billion by 2033. This steady growth is primarily attributed to government immunization initiatives, rising birth rates in emerging economies, and ongoing innovation in vaccine formulations. As per our latest research, the market’s upward trajectory is further reinforced by the growing emphasis on preventive healthcare and the integration of varicella vaccination into national immunization schedules across various regions.

One of the core growth factors for the varicella vaccines market is the increasing recognition of the severe complications associated with varicella-zoster virus (VZV) infections, especially among immunocompromised individuals and adults. The implementation of universal childhood immunization programs in several countries has led to a significant reduction in varicella incidence, hospitalizations, and mortality rates. This success has prompted additional nations to integrate varicella vaccines into their routine immunization schedules, further expanding the market base. Moreover, the World Health Organization (WHO) and other international health bodies actively promote varicella vaccination, especially in regions with high disease burden, which is expected to sustain market growth in the foreseeable future.

Another pivotal driver for the varicella vaccines market is the advancement in vaccine technology, particularly the development of combination vaccines that protect against multiple diseases in a single shot. These innovations enhance patient compliance, reduce the number of injections required, and streamline immunization logistics for healthcare providers. The increasing adoption of combination varicella vaccines, such as the measles-mumps-rubella-varicella (MMRV) vaccine, is particularly notable in developed markets where healthcare infrastructure supports the widespread use of advanced vaccines. Furthermore, ongoing research and development activities aim to improve vaccine efficacy, safety profiles, and storage stability, making varicella immunization more accessible in low-resource settings and further fueling market expansion.

The market is also benefiting from the growing emphasis on adult immunization, especially as the global population ages and the risk of severe varicella complications in adults becomes more pronounced. Public health campaigns and educational initiatives targeting adult populations, healthcare workers, and at-risk groups are contributing to increased vaccine uptake beyond the pediatric segment. Additionally, the expansion of distribution channels, including hospital pharmacies, retail clinics, and online pharmacies, has improved vaccine accessibility and convenience for both healthcare providers and recipients. These factors collectively create a favorable environment for sustained growth in the varicella vaccines market over the next decade.

Regionally, North America continues to dominate the varicella vaccines market, accounting for the largest share in 2024, followed closely by Europe and the Asia Pacific. The United States, in particular, benefits from comprehensive immunization programs, high healthcare expenditure, and robust public health infrastructure. Meanwhile, the Asia Pacific region is expected to witness the fastest growth over the forecast period, driven by rising birth rates, expanding healthcare access, and increasing government investments in immunization programs. Latin America and the Middle East & Africa are also poised for steady growth, supported by international health initiatives and the gradual integration of varicella vaccination into national immunization schedules. These regional dynamics underscore the global nature of the market and highlight the diverse opportunities for stakeholders across different geographies.

Product Type Analysis

The product type segment of the varicella vaccines market is primarily divided into monovalent varicella vaccines and combination varicella vaccines. Monovalent varicella vaccines, which target only the varicella-zoster virus, have been the traditional choice for routine immunization and outbreak control. These vaccines are wi

Respondent descriptions.

By 2021, adults aged 65 and older experienced 6.52 million new varicella and herpes zoster cases globally, with age-standardized incidence rates rising while death and disability-adjusted life years declined, highlighting shifting disease burden patterns. The varicella zoster HHV-3 infections epidemiology forecast by Expert Market Research indicates that the cases are expected to rise in the coming years, highlighting the demand for effective preventive and treatment measures.

Summary of case vignettesb'*'.

Use of antivirals and antibiotics for vignettes with and without complications.

IntroductionDespite vaccination, there were more than 100,000 annual cases of varicella in the United States in 2013–2014. Individuals at highest risk of developing severe or complicated varicella include immunocompromised people, preterm infants, and pregnant women. Varicella zoster immune globulin (human) (VARIZIG) is recommended by the CDC for postexposure prophylaxis to prevent or attenuate varicella-zoster virus infection in high-risk individuals. Contemporary information on administration of VARIZIG is limited.MethodsThis open-label, expanded-access program provided VARIZIG to physician-identified, high-risk participants exposed to varicella. Participants included immunocompromised children/adults, infants (preterm, newborns whose mothers had varicella onset within 5 days before or 2 days after delivery, and those aged 100 pox, pneumonia, or encephalitis) were assessed up to 42 days after administration.ResultsThe varicella outcome population (n = 507) included 263 immunocompromised participants (32 adults, 231 children), 137 pregnant women, 105 infants, and 2 healthy adults with no history of varicella. Varicella incidence was 4.5% in immunocompromised participants, 7.3% in pregnant women, and 11.5% in infants. The incidence of varicella was similar when comparing VARIZIG administration ≤ 96 hours vs > 96 hours (up to 10 days) postexposure in the entire population (6.2% vs. 9.4%, respectively), and also in each subgroup. Of 34 participants with varicella, 5 developed > 100 pox and 1 developed pneumonia and encephalitis. There were no product-related deaths and only 1 serious adverse event (serum sickness) considered probably related to VARIZIG.ConclusionPostexposure administration of VARIZIG was associated with low rates of varicella in high-risk participants, regardless of when administered within 10 days postexposure. VARIZIG was well-tolerated and safe in high-risk participants.

Country and age-specific number of varicella cases in the community, primary care visits, hospitalizations and deaths. (XLSX 24Â kb)

Brazil: Hospitalizations caused by varicella and HZ in patients ≥65 years of age in 2010–2019.

In-hospital mortality analysed by multilevel logistic regression model, log LOS and log TC by multilevel linear regression model, data year by random intercept. AOR: Adjusted odds ratio; AIDS: Acquired immunodeficiency syndrome; B: coefficient; LOS: Length of stay; TC: Total charge.Multivariate analyses of OI and other factors on in-hospital mortality and health care costs.

AIDS: Acquired immunodeficiency syndrome; IQR: Interquartile range, LOS: Length of stay, TC: Total charge.a Median age (interquartile range): 68 (15)b Kruskal-Wallis test, all others by chi-square testPatient characteristics categorized by age.